Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation

Ofrat Beyar-Katz, Noa Lavi, Shimrit Ringelstein-Harlev, Israel Henig, Dana Yehudai-Ofir, Nuhad Haddad, Riva Fineman, Yishai Ofran, Yuval Nov, Dvora Sahar, Nivin Moustafa-Hawash, Jacob M. Rowe, Tsila Zuckerman

Research output: Contribution to journalArticlepeer-review

Abstract

Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18–inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) (p =.001) and overall survivals (OS) (p =.0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% (p =.0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.

Original languageEnglish
Pages (from-to)2449-2456
Number of pages8
JournalLeukemia and Lymphoma
Volume60
Issue number10
DOIs
StatePublished - 24 Aug 2019
Externally publishedYes

Keywords

  • Acute myeloid leukemia (AML)
  • autologous SCT (ASCT)
  • core-binding factor (CBF) translocation
  • NPM1 mutation

Fingerprint

Dive into the research topics of 'Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation'. Together they form a unique fingerprint.

Cite this